The Europe lyophilized injectable market is expected to grow from US$ 808.34 million in 2022 to US$ 1,108.45 million by 2028. It is estimated to grow at a CAGR of 5.4% from 2022 to 2028.
Increasing Demand for Contract Research Manufacturing Services
Freeze drying, or lyophilization, is a drying process that consists of the sublimation of ice crystals into vapor. Lyophilization is a process based on negative temperatures and the product's activity and stability. Moreover, in this process, active ingredients are better retained while limiting any damage to the product and avoiding any degradation of the molecules. Thus, freeze-drying is especially popular in pharmaceutical and diagnostic sectors. The increased quality and extended shelf life of lyophilized injectable drugs are creating opportunities to implement the lyophilization process in product manufacturing. Contract manufacturing and research services are in huge demand, delivering lyophilized injectable drugs to offer high-quality products to end users. Moreover, many pharmaceutical companies are refocusing on their core capabilities, such as research and development, leading to divestments of in-house manufacturing capacities, which is growing the demand for contract research and manufacturing services (CRAMs) for manufacturing. Furthermore, CRAMs play crucial roles in providing additional capacities to mitigate the risk of supply shortages by offering additional sites for pharmaceutical companies with multisite supply strategies and backup capacities. Furthermore, safe transit, extended pharmaceutical storage life, and many other advantages offered by lyophilized injectables are increasing the adoption of the lyophilization technique by many enterprises across the region.
Market Overview
The Europe lyophilized injectable market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the market in 2022. Germany has a well-developed healthcare system. All legal & German residents are entitled to free necessary medical help, funded by a statutory contribution system. All residents must have medical insurance covering outpatient, inpatient, medical health, and prescription drug. Respiratory disease is one of the most common causes of death in Germany, which includes lung disorders and cancer. Moreover, changing lifestyles among the young population led to an increase in metabolic and autoimmune disorders, fueling the demand for lyophilized injectables. Respiratory disorders are one of the common causes of death along with lung cancer which are further supported by the increase in cardiovascular disorders which accounts for approximately 40% of deaths in Germany. According to the WHO 2020 report, Lung cancer is the third leading cause of death among the German population, with a prevalence rate of 10.3% of the total cancer cases. On the other hand, due to developed healthcare facilities and a rise in the prevalence of infectious diseases, Germany has a broad spectrum of antibiotics, leading to the increased use of antibiotics daily, creating the demand for lyophilized injectables. Moreover, high cost of transportation, increase in carbon footprints, and long shelf life have increased the demand for lyophilized drugs in the country.
Europe Lyophilized Injectable Market Revenue and Forecast to 2028 (US$ Million)
Europe Lyophilized Injectable Market Segmentation
The Europe lyophilized injectable market is segmented based on type of packaging, type of delivery, indication, end user, and country.
In terms of type of delivery, the Europe lyophilized injectable market is categorized into prefilled diluent syringes, single-step devices, proprietary reconstitution devices, and multi-step devices. The prefilled diluent syringes segment held the largest market share in 2022.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 808.34 Million |
| Market Size by 2028 | US$ 1,108.45 Million |
| CAGR (2022 - 2028) | 5.4% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Type of Packaging
|
|
Regions and Countries Covered
|
|
| Europe | UK, Germany, France, Russia, Italy, Rest of Europe |
| Market leaders and key company profiles |
|
The Europe Lyophilized Injectable Market is valued at US$ 808.34 Million in 2022, it is projected to reach US$ 1,108.45 Million by 2028.
As per our report Europe Lyophilized Injectable Market, the market size is valued at US$ 808.34 Million in 2022, projecting it to reach US$ 1,108.45 Million by 2028. This translates to a CAGR of approximately 5.4% during the forecast period.
The Europe Lyophilized Injectable Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Lyophilized Injectable Market report:
The Europe Lyophilized Injectable Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Lyophilized Injectable Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Lyophilized Injectable Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For Europe Lyophilized Injectable Market
